Feasibility of β-sheet breaker peptide-H102 treatment for Alzheimer's disease based on β-Amyloid hypothesis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Lin, Lai Xiang ^b   Bo, Xiang Yu ^a   Tan, Yuan Zhen ^a   Sun, Feng Xian ^a   Song, Ming ^a   Zhao, Juan ^a   Ma, Zhi Hong ^a   Li, Mei ^a   Zheng, Kai Jun ^a   Xu, Shu Mei ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Metabolic Diseases Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3; HISTIDINYLLYSYLGLUTAMINYLLEUCYLPROPYLPHENYLALANYLPHENYLALANYLGLUTAMYLGLUTAMYLASPARTIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PHOSPHOPROTEIN PHOSPHATASE 2A; POLYPEPTIDE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; PEPTIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME DEGRADATION; FEASIBILITY STUDY; HIPPOCAMPAL CA1 REGION; IMMUNOHISTOCHEMISTRY; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MOTIF; TRANSGENIC MOUSE; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CHEMISTRY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN SECONDARY STRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PEPTIDES; PROTEIN STRUCTURE, SECONDARY;

EID: 84910633282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112052     Document Type: Article

References (49)

1. Carrell RW, Lomas D.A. (1997) Conformational disease. Lancet 350: 134-138.
2. Soto C (1999) Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. J Mol Med (Berl) 77: 412-418.
3. Soto C (2001) Protein misfolding and disease; protein refolding and therapy. FEBS Lett 498: 204-207.
4. Kelly JW (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6: 11-17.
5. Soto C (1999) Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today 5: 343-350.
6. Iversen LL, Mortishire-Smith RJ, Pollack S.J., Shearman M.S. (1995) The toxicity in vitro of beta-amyloid protein. Biochem J 311 (Pt 1): 1-16.
7. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: A23-31.
8. Sipe JD, Cohen A.S. (2000) Review: history of the amyloid fibril. J Struct Biol 130: 88-98.
9. Hardy J, Selkoe D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
10. Walsh DM, Selkoe D.J. (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44: 181-193.
11. Joseph J, Shukitt-Hale B, Denisova N.A., Martin A., Perry G, et al. (2001) Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging 22: 131-146.
12. Robinson SR, Bishop G.M. (2002) Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol Aging 23: 1051-1072.
13. Chou PY, Fasman G.D. (1978) Empirical predictions of protein conformation. Annu Rev Biochem 47: 251-276.
14. Wang Z, Chang L, Klein W.L., Thatcher GR, Venton D.L. (2004) Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. J Med Chem 47: 3329-3333.
15. Hilbich C, Kisters-Woike B, Reed J., Masters CL, Beyreuther K. (1992) Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol 228: 460-473.
16. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697.
17. Soto C, Castano EM, Frangione B, Inestrosa N.C. (1995) The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem 270: 3063-3067.
18. Estrada LD, Soto C. (2006) Inhibition of protein misfolding and aggregation by small rationally-designed peptides. Curr Pharm Des 12: 2557-2567.
19. Estrada LD, Soto C. (2007) Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr Top Med Chem 7: 115-126.
20. Soto C, Kindy MS, Baumann M, Frangione B. (1996) Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 226: 672-680.
21. Adessi C, Soto C. (2002) Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem 9: 963-978.
22. Adessi C, Frossard MJ, Boissard C, Fraga S., Bieler S, et al. (2003) Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem 278: 13905-13911.
23. Zhao J, Xu S.M. (2008) Inhibitory activities of β-sheet breakers on aggregation and toxicity of β-amyloid protein. Chin J New Drugs Clin Rem 27: 675-679.
24. Song M, Li M, Lin L.X., SM X. (2010) Effects of H102 on IDE and NEP in brains of APP transgenic mice. J Tianjin Med Univ 16: 566-569.
25. Wang M, Xu SM, Ma Z.H. (2010) Effects of H102 on synapse-related protein synaptophysin of APP transgenic mice. Tianjin Med J 38: 405-408.
26. Yamada N, Hattori A, Hayashi T., Nishikawa T, Fukuda H, et al (2004) Improvement of scopolamine-induced memory impairment by Z-ajoene in the water maze in mice. Pharmacol Biochem Behav 78: 787-791.
27. Li M, Lin LX, Xu S.M. (2009) Effects of H102 on cholinergic system and free radicals of APP transgenic mouse. Chin J New Drugs Clin Rem 28: 106-110.
28. Chiti F, Dobson C.M. (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333-366.
29. Xia W, Zhang J, Kholodenko D., Citron M, Podlisny MB, et al (1997) Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem 272: 7977-7982.
30. Nadimpally KC, Paul A, Mandal B. (2014) Reversal of aggregation using beta-breaker dipeptide containing peptides: Application to Abeta(1-40) self-assembly and its inhibition. ACS Chem Neurosci 5: 400-408.
31. Vitiello G, Grimaldi M, Ramunno A., Ortona O, De Martino G, et al. (2010) Interaction of a beta-sheet breaker peptide with lipid membranes. J Pept Sci 16: 115-122.
32. Vitiello G, Grimaldi M, D'Ursi AM, D'Errico G (2012) The iAbeta5p beta-breaker peptide regulates the Abeta(25-35) interaction with lipid bilayers through a cholesterol-mediated mechanism. Biochem Biophys Res Commun 417: 88-92.
33. Tjernberg LO, Naslund J, Lindqvist F., Johansson J, Karlstrom AR, et al (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271: 8545-8548.
34. MA ZH, Xu S.M. (2008) The protective effect of H102 on neurotoxicity induced by Ab42. Tianjin Med J 36: 198-200.
35. Casal C, Serratosa J, Tusell J.M. (2004) Effects of beta-AP peptides on activation of the transcription factor NF-kappaB and in cell proliferation in glial cell cultures. Neurosci Res 48: 315-323.
36. Akiyama H (2006) [Abeta, tau and alpha-synuclein and glial cells]. Nihon Shinkei Seishin Yakurigaku Zasshi 26: 23-31.
37. Li Y, Liu L, Barger S.W., Griffin W.S. (2003) Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 23: 1605-1611.
38. Kitazawa M, Oddo S, Yamasaki T.R., Green KN, LaFerla F.M. (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25: 8843-8853.
39. Griffin WS, Sheng JG, Roberts G.W., Mrak R.E. (1995) Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 54: 276-281.
40. Gong CX, Shaikh S, Wang J.Z., Zaidi T., Grundke-Iqbal I, et al. (1995) Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65: 732-738.
41. Reynolds CH, Nebreda AR, Gibb G.M., Utton MA, Anderton B.H. (1997) Reactivating kinase/p38 phosphorylates tau protein in vitro. J Neurochem 69: 191-198.
42. Fu AL, Li Q, Dong Z.H., Huang SJ, Wang YX, et al. (2004) Alternative therapy of Alzheimer's disease via supplementation with choline acetyltransferase. Neurosci Lett 368: 258-262.
43. Etienne P, Robitaille Y, Wood P., Gauthier S, Nair NP, et al (1986) Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience 19: 1279-1291.
44. Inestrosa NC, Urra S, Colombres M. (2004) Acetylcholinesterase (AChE)-amyloid-beta-peptide complexes in Alzheimer's disease. the Wnt signaling pathway. Curr Alzheimer Res 1: 249-254.
45. Geula C, Mesulam M.M. (1989) Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience 33: 469-481.
46. Butterfield DA, Drake J, Pocernich C., Castegna A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7: 548-554.
47. Draper HH, Hadley M. (1990) Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 186: 421-431.
48. Banks WA, Kastin A.J. (1996) Passage of peptides across the blood-brain barrier: pathophysiological perspectives. Life Sci 59: 1923-1943.
49. al-Obeidi F., Hruby VJ, Sawyer T.K. (1998) Peptide and peptidomimetic libraries. Molecular diversity and drug design. Mol Biotechnol 9: 205-223.